697 related articles for article (PubMed ID: 17332884)
1. ECM remodeling in hypertensive heart disease.
Berk BC; Fujiwara K; Lehoux S
J Clin Invest; 2007 Mar; 117(3):568-75. PubMed ID: 17332884
[TBL] [Abstract][Full Text] [Related]
2. Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress.
Kandalam V; Basu R; Moore L; Fan D; Wang X; Jaworski DM; Oudit GY; Kassiri Z
Circulation; 2011 Nov; 124(19):2094-105. PubMed ID: 21986284
[TBL] [Abstract][Full Text] [Related]
3. Effects of fenofibrate on cardiac remodeling in aldosterone-induced hypertension.
Lebrasseur NK; Duhaney TA; De Silva DS; Cui L; Ip PC; Joseph L; Sam F
Hypertension; 2007 Sep; 50(3):489-96. PubMed ID: 17606858
[TBL] [Abstract][Full Text] [Related]
4. Molecular imaging of the cardiac extracellular matrix.
de Haas HJ; Arbustini E; Fuster V; Kramer CM; Narula J
Circ Res; 2014 Feb; 114(5):903-15. PubMed ID: 24577969
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
[TBL] [Abstract][Full Text] [Related]
6. Extracellular matrix biology: a new frontier in linking the pathology and therapy of hypertension?
Tayebjee MH; MacFadyen RJ; Lip GY
J Hypertens; 2003 Dec; 21(12):2211-8. PubMed ID: 14654734
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II, oxidative stress, and extracellular matrix degradation during transition to LV failure in rats with hypertension.
Takenaka H; Kihara Y; Iwanaga Y; Onozawa Y; Toyokuni S; Kita T
J Mol Cell Cardiol; 2006 Dec; 41(6):989-97. PubMed ID: 16979182
[TBL] [Abstract][Full Text] [Related]
8. A look between the cardiomyocytes: the extracellular matrix in heart failure.
Miner EC; Miller WL
Mayo Clin Proc; 2006 Jan; 81(1):71-6. PubMed ID: 16438481
[TBL] [Abstract][Full Text] [Related]
9. Role of matrix metalloproteinases in hypertension-associated cardiac fibrosis.
López B; González A; Díez J
Curr Opin Nephrol Hypertens; 2004 Mar; 13(2):197-204. PubMed ID: 15202614
[TBL] [Abstract][Full Text] [Related]
10. K(ATP) activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function.
Gao S; Long CL; Wang RH; Wang H
Cardiovasc Res; 2009 Aug; 83(3):444-56. PubMed ID: 19304734
[TBL] [Abstract][Full Text] [Related]
11. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy.
Li YY; Feng YQ; Kadokami T; McTiernan CF; Draviam R; Watkins SC; Feldman AM
Proc Natl Acad Sci U S A; 2000 Nov; 97(23):12746-51. PubMed ID: 11070088
[TBL] [Abstract][Full Text] [Related]
12. Beta-blocker improves survival, left ventricular function, and myocardial remodeling in hypertensive rats with diastolic heart failure.
Kobayashi M; Machida N; Mitsuishi M; Yamane Y
Am J Hypertens; 2004 Dec; 17(12 Pt 1):1112-9. PubMed ID: 15607617
[TBL] [Abstract][Full Text] [Related]
13. Macrophages dictate the progression and manifestation of hypertensive heart disease.
Kain D; Amit U; Yagil C; Landa N; Naftali-Shani N; Molotski N; Aviv V; Feinberg MS; Goitein O; Kushnir T; Konen E; Epstein FH; Yagil Y; Leor J
Int J Cardiol; 2016 Jan; 203():381-95. PubMed ID: 26539962
[TBL] [Abstract][Full Text] [Related]
14. Long-term administration of nifedipine attenuates cardiac remodeling and diastolic heart failure in hypertensive rats.
Yamada T; Nagata K; Cheng XW; Obata K; Saka M; Miyachi M; Naruse K; Nishizawa T; Noda A; Izawa H; Kuzuya M; Okumura K; Murohara T; Yokota M
Eur J Pharmacol; 2009 Aug; 615(1-3):163-70. PubMed ID: 19501083
[TBL] [Abstract][Full Text] [Related]
15. Pathophysiology of Hypertensive Heart Disease: Beyond Left Ventricular Hypertrophy.
Nwabuo CC; Vasan RS
Curr Hypertens Rep; 2020 Feb; 22(2):11. PubMed ID: 32016791
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression.
Polyakova V; Hein S; Kostin S; Ziegelhoeffer T; Schaper J
J Am Coll Cardiol; 2004 Oct; 44(8):1609-18. PubMed ID: 15489093
[TBL] [Abstract][Full Text] [Related]
17. Extracellular matrix remodeling in hypertensive heart disease.
Shirwany A; Weber KT
J Am Coll Cardiol; 2006 Jul; 48(1):97-8. PubMed ID: 16814654
[No Abstract] [Full Text] [Related]
18. Mechanisms of disease: pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease.
Díez J; González A; López B; Querejeta R
Nat Clin Pract Cardiovasc Med; 2005 Apr; 2(4):209-16. PubMed ID: 16265485
[TBL] [Abstract][Full Text] [Related]
19. Myocardial Interstitial Fibrosis in Hypertensive Heart Disease: From Mechanisms to Clinical Management.
González A; López B; Ravassa S; San José G; Latasa I; Butler J; Díez J
Hypertension; 2024 Feb; 81(2):218-228. PubMed ID: 38084597
[TBL] [Abstract][Full Text] [Related]
20. Fibrosis and heart failure.
Segura AM; Frazier OH; Buja LM
Heart Fail Rev; 2014 Mar; 19(2):173-85. PubMed ID: 23124941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
